Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver transplantation in the next decade. Cenicriviroc (CVC), a dual chemokine receptor 2 and 5 antagonist, prevents macrophage trafficking and is under clinical investigation fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruger, Annie J., Fuchs, Bryan C., Masia, Ricard, Holmes, Jacinta A., Salloum, Shadi, Sojoodi, Mozhdeh, Ferreira, Diego S., Rutledge, Stephanie M., Caravan, Peter, Alatrakchi, Nadia, Vig, Pam, Lefebvre, Eric, Chung, Raymond T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944590/
https://www.ncbi.nlm.nih.gov/pubmed/29761169
http://dx.doi.org/10.1002/hep4.1160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944590/
https://www.ncbi.nlm.nih.gov/pubmed/29761169
http://dx.doi.org/10.1002/hep4.1160

Ejemplares similares